CN111808088B - 化合物tersaphilone B和E及其制备方法和在制备抗肿瘤药物中的应用 - Google Patents
化合物tersaphilone B和E及其制备方法和在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN111808088B CN111808088B CN202010647520.7A CN202010647520A CN111808088B CN 111808088 B CN111808088 B CN 111808088B CN 202010647520 A CN202010647520 A CN 202010647520A CN 111808088 B CN111808088 B CN 111808088B
- Authority
- CN
- China
- Prior art keywords
- tersaphilone
- compound
- ethyl acetate
- fraction
- volume ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 98
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 13
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 10
- 241000797114 Phomopsis tersa Species 0.000 claims abstract description 16
- 238000000855 fermentation Methods 0.000 claims abstract description 14
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 6
- 206010018338 Glioma Diseases 0.000 claims abstract description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 6
- 201000007270 liver cancer Diseases 0.000 claims abstract description 5
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 28
- 238000004809 thin layer chromatography Methods 0.000 claims description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 12
- 244000061456 Solanum tuberosum Species 0.000 claims description 11
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 11
- 229940125782 compound 2 Drugs 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 241000209094 Oryza Species 0.000 claims description 9
- 235000007164 Oryza sativa Nutrition 0.000 claims description 9
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 235000009566 rice Nutrition 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 238000011894 semi-preparative HPLC Methods 0.000 claims description 6
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000009630 liquid culture Methods 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002024 ethyl acetate extract Substances 0.000 claims description 2
- 239000002054 inoculum Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 238000005100 correlation spectroscopy Methods 0.000 description 6
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000002211 ultraviolet spectrum Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 4
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 238000004896 high resolution mass spectrometry Methods 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001480007 Phomopsis Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HNVJWWBKFFDQAA-NRKPLWJESA-N [(7r,8r,8ar)-7-hydroxy-7-methyl-6-oxo-3-[(e)-prop-1-enyl]-8,8a-dihydro-1h-isochromen-8-yl] 2,4-dihydroxy-6-methylbenzoate Chemical group O([C@H]1[C@@](C)(O)C(=O)C=C2C=C(OC[C@@H]21)/C=C/C)C(=O)C1=C(C)C=C(O)C=C1O HNVJWWBKFFDQAA-NRKPLWJESA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- -1 azaphilone compound Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了化合物tersaphilone B和E及其制备方法和在制备抗肿瘤药物中的应用。本发明所述的化合物tersaphilone B和E是从海洋真菌Phomopsis tersa FS441的发酵培养物中分离制备得到的。经试验证明,化合物tersaphilone B和E对肝癌细胞HepG‑2、乳腺癌细胞MCF‑7、神经胶质瘤细胞SF‑268和非小细胞肺癌细胞A549的IC50值范围为5.4~36.7μM,显示出比较显著的抗肿瘤活性,可以用于制备抗肿瘤药物。
Description
技术领域
本发明属于医药生物技术领域,具体涉及化合物tersaphilone B和E及其制备方法和在制备抗肿瘤药物中的应用。
背景技术
Phomopsis属真菌能够产生结构多样的新颖次级代谢产物,包括萜类、细胞分裂素类、聚酮类、甾体、内脂以及烯醇等多种类型的天然产物。并且,这些天然产物大部分具有广泛的抗肿瘤、抗疟原虫、抗炎等生物活性。Azaphilones类化合物是一类真菌代谢产物,结构特点是由吡喃酮与喹诺酮组成的基本核心骨架分子。该类型分子已被报道具有多种生物活性。
发明内容:
本发明的第一个目的是提供具有抗肿瘤活性的海洋来源Azaphilones化合物tersaphiloneB和E。
本发明的Azaphilones化合物,其结构如式(I)中任一所示:
其中化合物1是化合物tersaphilone B,化合物2是化合物tersaphilone E。
本发明的第二个目的是提供一种化合物tersaphilone B和E的制备方法,该制备方法中所述的化合物tersaphilone B和E是从海洋真菌Phomopsis tersa FS441的发酵培养物中分离制备得到的,具体包括以下步骤:
(1)制备海洋真菌Phomopsis tersa FS441的固体发酵培养物,用乙酸乙酯萃取该固体发酵培养物,将乙酸乙酯萃取液经浓缩后得浸膏;
(2)浸膏经过硅胶柱层析,用石油醚-乙酸乙酯以体积比为10:1,5:1,2:1,1:1,0:1和二氯甲烷-甲醇以体积比为10:1,5:1,0:1分别作为洗脱剂,梯度洗脱;收集石油醚-乙酸乙酯体积比5:1洗脱获得的且经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.3-0.4的组分Fr.4;收集石油醚-乙酸乙酯体积比1:1洗脱获得的且经TLC薄层层析以正己烷:乙酸乙酯=1:1v/v展开得Rf=0.4-0.5的组分Fr.5。
将组分Fr.4经正相柱色谱,用甲醇-水体积比30:70,20:80,10:90,0:100梯度洗脱,收集经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.30-0.40的组分Fr.4.3,将组分Fr.4.3经纯化得到化合物tersaphilone B;
将组分Fr.5经反相柱色谱,用甲醇-水体积比70:30,80:20,90:10,100:0梯度洗脱,收集甲醇-水体积比80:20洗脱组分Fr.5.9,组分Fr.5.9经过进一步的正相硅胶柱,用二氯甲烷:甲醇40:1,30:1,20:1,10:1,5:1,2:1v/v梯度洗脱,收集经TLC薄层层析以二氯甲烷:甲醇=10:1v/v展开得Rf=0.55-0.65的组分Fr.5.9.3,将组分Fr.5.9.3纯化得到化合物tersaphiloneE。
优选,所述的将组分Fr.4.3经纯化得到化合物tersaphilone B是经制备液相,使用YMC-pack ODS-A柱,溶剂体系为甲醇:水90:10v/v,流速为5mL/min,收集经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.55-0.65的组分Fr.4.3.5,将组分Fr.4.3.5用半制备HPLC分离纯化,使用CHIRALPAK IC柱,溶剂体系为乙腈:水70:30v/v,流速为2mL/min,得到保留时间为11.5min的化合物tersaphilone B。
优选,所述的将组分Fr.5.9.3纯化得到化合物tersaphilone E是将组分Fr.5.9.3用半制备HPLC分离纯化,使用CHIRALPAK IC柱,溶剂体系为异丙醇:正己烷50:50v/v,流速为2mL/min,得到保留时间为10.0min的化合物tersaphilone E。
所述的制备海洋真菌Phomopsis tersa FS441的固体发酵培养物具体步骤为:挑取FS441的菌丝接种于马铃薯葡萄糖液体培养基中,在28℃、120r/min条件下培养5天,制得种子液,然后将种子液按0.1mL/g的接种量接种于大米培养基中,28℃条件下培养30天,制得FS441的固体发酵培养物,所述的马铃薯葡萄糖液体培养基,每升是通过以下方法配制的:用500mL的纯水煮200g的马铃薯,煮沸20min,过滤得马铃薯汁,再加入葡萄糖20g、KH2PO43g、MgSO41.5g、维生素B110mg,用水补足至1000mL,灭菌制得;所述的大米培养基是通过以下方法配制的:按每280g大米与300mL质量体积比为0.5%g/ml的粗海盐水溶液混合灭菌制得。
本发明通过实验发现,化合物tersaphilone B和tersaphilone E对肝癌细胞HepG-2、乳腺癌细胞MCF-7、神经胶质瘤细胞SF-268和非小细胞肺癌细胞A549的IC50值范围为5.4~36.7μM。阳性对照物顺铂对以上四种肿瘤细胞株的IC50值分别为2.4、3.2、3.3和1.6μM。此结果表明:本发明的化合物tersaphilone B和E均具有比较显著的抗肿瘤活性。
因此,本发明的第三个目的是提供化合物tersaphilone B和/或tersaphilone E,或其药用盐在制备抗肿瘤药物中的应用。所述的抗肿瘤药物优选为抗肝癌、乳腺癌、神经胶质瘤或非小细胞肺癌药物。
本发明的第四个目的是提供一种抗肿瘤药物,该抗肿瘤药物包含化合物tersaphilone B和E中的至少一种,或其药用盐作为活性成分。优选,所述的抗肿瘤药物为抗肝癌、乳腺癌、神经胶质瘤或非小细胞肺癌药物。
本发明的第五个目的是提供海洋真菌Phomopsis tersa FS441在制备化合物tersaphilone B和/或tersaphilone E中的应用。
与现有技术相比,本发明的优势在于:
本发明从海洋真菌Phomopsis tersa FS441中分离制备得到化合物tersaphiloneB和E,该类化合物tersaphilone B和E具有比较显著的抗肿瘤活性,可以用于制备抗肿瘤药物,为研究与开发新的抗肿瘤药物提供了候选化合物,为开发利用海洋微生物来源的天然活性物质提供了科学依据。
本发明的海洋真菌Phomopsis tersa FS441已公开于Shanchong Chen,ZhaomingLiu,Haibo Tan,Yuchan Chen,Saini Li,Haohua Li,H.Guo,Shuang Zhu,Hongxin Liu,Weimin Zhang.Tersone A-G,new pyridone alkaloids from the deep-sea fungusPhomopsis tersa.Marine Drugs,2019,17,394。该菌株本申请人也持有,并保证自申请日起20年内向公众提供。
附图说明
图1是化合物tersaphilone B的1H NMR谱;
图2是化合物tersaphilone B的13C NMR谱;
图3是化合物tersaphilone B的DEPT谱;
图4是化合物tersaphilone B的HSQC谱;
图5是化合物tersaphilone B的HMBC谱;
图6是化合物tersaphilone B的NOESY谱;
图7是化合物tersaphilone B的HR-ESIMS谱;
图8是化合物tersaphilone B的CD谱;
图9是化合物tersaphilone B的UV谱;
图10是化合物tersaphilone B的IR谱;
图11是化合物tersaphilone E的1HNMR谱;
图12是化合物tersaphilone E的13C NMR谱;
图13是化合物tersaphilone E的COSY谱;
图14是化合物tersaphilone E的HSQC谱;
图15是化合物tersaphilone E的HMBC谱;
图16是化合物tersaphilone E的NOESY谱
图17是化合物tersaphilone E的HR-ESIMS谱;
图18是化合物tersaphilone E的CD谱;
图19是化合物tersaphilone E的UV谱;
图20是化合物tersaphilone E的IR谱;
图21是化合物tersaphilone B和tersaphilone E的1H-1H COSY和HMBC相关图。
具体实施方式
以下实施例是对本发明的进一步说明,而不是对本发明的限制。
实施例1
1、海洋真菌Phomopsis tersa FS441的分离纯化和鉴定
本发明的海洋真菌Phomopsis tersa FS441是2016年5月,从印度洋深海沉积物(88°58.640'N,0°00.307'E,水深3000米)中分离得到的,经ITS序列分析鉴定,GenBank基因登录号为:MK592793,经blast比对,同源分析,鉴定该菌株属于Phomopsis属真菌,命名为Phomopsis tersa FS441。
2、Phomopsis tersa FS441的固体发酵
将活化的深海真菌Phomopsis tersa FS441菌丝体接种于马铃薯葡萄糖液体培养基(每升培养基是通过以下方法配制的:用500mL的纯水煮200g的马铃薯,煮沸20min,过滤得马铃薯汁,再加入葡萄糖20g、KH2PO43g、MgSO41.5g、维生素B110mg,用水补足至1000mL,灭菌制得)中,在28℃、120r/min条件下培养5天,制得种子液,然后将种子液按0.1mL/g大米培养基的接种量接种于大米培养基(该培养基是通过以下方法配制的:将280g大米与300mL质量体积比为0.5%mg/ml的粗海盐水溶液混合,121℃高压灭菌20min,冷却,制得)中,28℃条件下培养30天,制得FS441的固体发酵培养物。
3、化合物tersaphilone B和/或D的制备
(1)往FS441的固体发酵培养物中加入乙酸乙酯,浸泡提取24小时,重复提取3次,提取液合并后经浓缩后得浸膏(177.9g)。
(2)浸膏经过硅胶柱层析,用石油醚-乙酸乙酯以体积比为10:1,5:1,2:1,1:1,0:1和二氯甲烷-甲醇以体积比为10:1,5:1,0:1分别作为洗脱剂,梯度洗脱;收集石油醚-乙酸乙酯体积比5:1洗脱获得的且经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.3-0.4的组分Fr.4;收集石油醚-乙酸乙酯体积比1:1洗脱获得的且经TLC薄层层析以正己烷:乙酸乙酯=1:1v/v展开得Rf=0.4-0.5的组分Fr.5。
将组分Fr.4经正相柱色谱,用甲醇-水体积比30:70,20:80,10:90,0:100梯度洗脱,得到3个亚组分Fr.4.1-Fr.4.3。收集经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.30-0.40的组分Fr.4.3,将组分Fr.4.3经制备液相,使用YMC-pack ODS-A柱(250×20mm,5μm,12nm),溶剂体系为甲醇:水90:10v/v,流速为5mL/min,得到组分Fr.4.3.1-Fr.4.3.12。收集经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.55-0.65的组分Fr.4.3.5,将组分Fr.4.3.5用半制备HPLC分离纯化,使用CHIRALPAK IC柱(250×10mm,5μm),溶剂体系为乙腈:水70:30v/v,流速为2mL/min,得到保留时间为11.5min的化合物tersaphiloneB(5.8mg)。
将组分Fr.5经反相柱色谱,用甲醇-水体积比70:30,80:20,90:10,100:0梯度洗脱,收集甲醇-水体积比80:20洗脱组分Fr.5.9。组分Fr.5.9经过进一步的正相硅胶柱,用二氯甲烷:甲醇40:1,30:1,20:1,10:1,5:1,2:1v/v梯度洗脱得到5个亚组分Fr.5.9.1-Fr.5.9.5。收集经TLC薄层层析以二氯甲烷:甲醇=10:1v/v展开得Rf=0.55-0.65的组分Fr.5.9.3,将组分Fr.5.9.3用半制备HPLC分离纯化,使用CHIRALPAK IC柱(250×10mm,5μm),溶剂体系为异丙醇:正己烷50:50v/v,流速为2mL/min,得到保留时间为10.0min的化合物tersaphiloneE(4.2mg)。
4、化合物tersaphilone B和D的结构鉴定
1H-NMR、13C-NMR、HMBC核磁共振谱图用BrukerAdvance-600核磁共振光谱仪测定,以四甲基硅烷(TMS)为内标;ESI-MS数据用VGAutospec-3000型质谱仪测定;紫外光谱用岛津UV-2600分光光度计测定,其结构鉴定如下:
如图1-21所示,图1是化合物tersaphilone B的1H NMR谱;图2是化合物tersaphiloneB的13C NMR谱;图3是化合物tersaphilone B的COSY谱;图4是化合物tersaphilone B的HSQC谱;图5是化合物I的HMBC谱;图6是化合物tersaphilone B的NOESY谱;图7是化合物tersaphilone B的HR-ESIMS谱;图8是化合物tersaphilone B的CD谱;图9是化合物tersaphilone B的UV谱;图10是化合物tersaphilone B的IR谱;
图11是化合物tersaphilone E的1HNMR谱;图12是化合物tersaphilone E的13CNMR谱;图13是化合物tersaphilone E的COSY谱;图14是化合物tersaphilone E的HSQC谱;图15是化合物tersaphilone E的HMBC谱;图16是化合物tersaphilone E的NOESY谱图17是化合物tersaphilone E的HR-ESIMS谱;图18是化合物tersaphilone E的CD谱;图19是化合物tersaphilone E的UV谱;图20是化合物tersaphilone E的IR谱。
图21是化合物tersaphilone B和tersaphilone E的1H-1H COSY和HMBC相关图。
化合物1为黄色粉末(其核磁数据如表1所示);根据HRESIMS[M+H]+m/z 461.1738,C25H29ClO6,计算值为461.1725,确定化合物的分子式为C25H28ClO6,不饱和度为11;1H-NMR谱显示一个典型的azaphilone骨架以及五个烯烃质子信号[δHδH 7.65(s,H-1),6.76(s,H-4),6.32(d,J=15.8Hz,H-9),7.15(d,J=15.8Hz,H-10),5.71(d,J=9.8Hz,H-12)];3个次甲基信号[δH 4.05(s,H-8),2.52(m,H-13),4.26(m,H-5′)];3个甲基氢信号[δH 0.87(m,H3-15),1.87(s,H3-16),1.02(d,J=6.7Hz,H3-17),1.57(s,H3-18),1.18(d,J=6.3Hz,H3-6′)]。13C-NMR谱以及HSQC谱显示化合物1中有24个碳信号,包括9个季碳(包括2个羰基碳),2个次甲基,8个亚甲基,以及5个甲基。化合物I的平面结构结构通过进一步分析其COSY、HSQC以及HMBC等二维谱图得以确定(图21),化合物I的绝对构型是通过计算ECD法得以确定。
化合物2为黄色固体(其核磁数据如表1所示);根据高分辨质谱(HRESIMS)[M+H]+m/z 493.1633,C25H29ClO8,计算值为493.1624,确定化合物的分子式为C25H28ClO8;通过分析其1D和2D谱图发现化合物2的谱图与化合物1的谱图具有极大的相似度,推测化合物2也为azaphilone类化合物。化合物2的1HNMR数据表明分子中含有4个烯烃质子信号[δH 6.34(1H,s,H-4),6.26(1H,d,J=15.6Hz,H-9),7.18(1H,d,J=15.6Hz,H-10),5.72(1H,d,J=9.8Hz,H-12)],3个次甲基信号[δH 6.10(1H,s,H-1),2.53(1H,m,H-13),3.92(1H,m,H-5′)],以及5个甲基信号[δH 0.89(3H,t,J=7.5Hz,H3-15),1.87(3H,s,H3-16),1.02(3H,d,J=6.7Hz,H3-17),1.70(3H,s,H3-18),1.00(3H,d,J=6.2Hz,H3-6′)]。分析化合物2的13C NMR和HSQC数据(Table 3)显示化合物2中包括5个甲基碳信号(δC 12.5,C-15;δC 12.4,C-16;δC 20.6,C-17;δC 18.7,C-18;δC 22.5,C-6′),七个次甲基碳信号(δC 102.5,C-4;δC 119.8,C-9;δC144.2,C-10;δC 149.1,C-12),2个亚甲基碳信号(δC 31.2,C-14;δC 39.4,C-4′),以及十一个季碳信号。最终,通过系统分析其二维谱(图21)确定了化合物2的平面结构。
表1化合物1和2的核磁数据(600MHz/150MHz,δinppm,Jin Hz)
*Notdetected;**DetectedbyHMBC
经过上述方法分离的目标化合物tersaphilone B和tersaphilone E的结构式如式(I)所示:
其中化合物1是化合物tersaphilone B,化合物2是化合物tersaphilone E。
实施例2
采用SRB法(Skehan P,Storeng R,Dominic S.New colorimetric cytotoxicityassay foranticancer-drug screening[J].JNatl Cance Inst,1990,82:1107–1112.)测试化合物tersaphilone B和tersaphilone E的抗肿瘤活性。
1、试验用试剂:将本发明制备的化合物tersaphilone B和tersaphilone E用二甲基亚砜(DMSO)溶解得浓度为10mg/mL的母液,再用RPMI-1640培养基稀释至所需浓度。阳性对照为顺铂水溶液。
本实验所用肿瘤细胞株为肝癌细胞HepG-2、乳腺癌细胞MCF-7、神经胶质瘤细胞SF-268和非小细胞肺癌细胞A549。
2、实验方法:取对数生长期的HepG-2、MCF-7、SF-268和A549细胞,用胰酶消化,台盼蓝染色计数,台盼蓝排斥实验检测细胞活力大于95%后,用新鲜RPMI-1640培养基调整细胞浓度为3×104个/mL,细胞接种于96孔板,每孔加入180μL的细胞悬液,并设3个空白孔调零,于37℃、5%CO2培养箱培养24h。待细胞贴壁后,每孔加入20μL一定浓度的上述tersaphilone B和D的溶液,阴性对照加20μLRPMI-1640培养基,以顺铂作阳性对照,每个做三个重复。置于37℃、5%CO2培养箱中培养72h后,加入50μL体积分数为50%的冷三氯醋酸水溶液固定细胞,4℃放置1h后用蒸馏水洗涤5次,空气中自然干燥。然后加入由体积分数1%冰醋酸水溶液配制的磺酰罗丹明B(Sulforhodamine B,SRB)4mg/mL溶液100μL/孔,室温中染色30min,去上清,用1%冰醋酸洗涤5次,空气干燥。最后加入200μL/孔,浓度为10mmol/mL的Tris溶液,用酶标仪测定570nm处的吸光值(A),用以下公式计算药物对细胞生长的抑制率:细胞生长抑制率(%)=(1-A样品组/A对照组)×100%。
3、实验结果:本发明制备的化合物tersaphilone B和E对四株肿瘤细胞的细胞毒性如表2所示。此结果表明:本发明的化合物tersaphilone B和E具有比较显著的抗肿瘤活性,因此,本发明为研究与开发新的抗肿瘤药物提供了候选化合物,为开发利用深海微生物来源的天然活性物质提供了科学依据。
表2化合物tersaphilone B和E的对癌细胞的抑制效果
以上仅是本发明的优选实施方式,应当指出的是,上述优选实施方式不应视为对本发明的限制,本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说,在不脱离本发明的精神和范围内,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (8)
2.一种权利要求1中所述的化合物tersaphilone B和E的制备方法,其特征在于,所述的化合物tersaphilone B和E是从海洋真菌Phomopsis tersa FS441的发酵培养物中分离制备得到的;
具体包括以下步骤:
(1)制备海洋真菌Phomopsis tersa FS441的固体发酵培养物,用乙酸乙酯萃取该固体发酵培养物,将乙酸乙酯萃取液经浓缩后得浸膏;
(2)浸膏经过硅胶柱层析,用石油醚-乙酸乙酯以体积比为10:1,5:1,2:1,1:1,0:1和二氯甲烷-甲醇以体积比为10:1,5:1,0:1分别作为洗脱剂,梯度洗脱;收集石油醚-乙酸乙酯体积比5:1洗脱获得的且经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.3-0.4的组分Fr.4;收集石油醚-乙酸乙酯体积比1:1洗脱获得的且经TLC薄层层析以正己烷:乙酸乙酯=1:1v/v展开得Rf=0.4-0.5的组分Fr.5;
将组分Fr.4经正相柱色谱,用甲醇-水体积比30:70,20:80,10:90,0:100梯度洗脱,收集经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.30-0.40的组分Fr.4.3,将组分Fr.4.3经纯化得到化合物tersaphilone B;
将组分Fr.5经反相柱色谱,用甲醇-水体积比70:30,80:20,90:10,100:0梯度洗脱,收集甲醇-水体积比80:20洗脱组分Fr.5.9,组分Fr.5.9经过进一步的正相硅胶柱,用二氯甲烷:甲醇以体积比为40:1,30:1,20:1,10:1,5:1,2:1梯度洗脱,收集经TLC薄层层析以二氯甲烷:甲醇=10:1v/v展开得Rf=0.55-0.65的组分Fr.5.9.3,将组分Fr.5.9.3纯化得到化合物tersaphilone E。
3.根据权利要求2所述的制备方法,其特征在于,所述的将组分Fr.4.3经纯化得到化合物tersaphilone B是经制备液相,使用YMC-pack ODS-A柱,溶剂体系为甲醇:水90:10v/v,流速为5mL/min,收集经TLC薄层层析以正己烷:乙酸乙酯=2:1v/v展开得Rf=0.55-0.65的组分Fr.4.3.5,将组分Fr.4.3.5用半制备HPLC分离纯化,使用CHIRALPAK IC柱,溶剂体系为乙腈:水70:30v/v,流速为2mL/min,得到保留时间为11.5min的化合物tersaphilone B。
4.根据权利要求2所述的制备方法,其特征在于,所述的将组分Fr.5.9.3纯化得到化合物tersaphilone E是将组分Fr.5.9.3用半制备HPLC分离纯化,使用CHIRALPAK IC柱,溶剂体系为异丙醇:正己烷50:50v/v,流速为2mL/min,得到保留时间为10.0min的化合物tersaphilone E。
5.根据权利要求2所述的制备方法,其特征在于,所述的步骤(1)制备海洋真菌Phomopsis tersa FS441的固体发酵培养物具体步骤为:挑取FS441的菌丝体接种于马铃薯葡萄糖液体培养基中,在28℃、120r/min条件下培养5天,制得种子液,然后将种子液按0.1mL/g的接种量接种于大米培养基中,28℃条件下培养30天,制得FS441的固体发酵培养物,所述的马铃薯葡萄糖液体培养基,每升是通过以下方法配制的:用500mL的纯水煮200g的马铃薯,煮沸20min,过滤得马铃薯汁,再加入葡萄糖20g、KH2PO4 3g、MgSO4 1.5g、维生素B1 10mg,用水补足至1000mL,灭菌制得;所述的大米培养基是通过以下方法配制的:按每280g大米与300mL质量体积比为0.5%g/mL的粗海盐水溶液混合灭菌制得。
6.权利要求1中所述的化合物tersaphilone B和/或tersaphilone E或其药用盐在制备抗肿瘤药物中的应用;所述的抗肿瘤药物为抗肝癌、乳腺癌、神经胶质瘤或非小细胞肺癌药物。
7.一种抗肿瘤药物,其特征在于,包含权利要求1中的化合物tersaphilone B和/或tersaphilone E或其药用盐作为活性成分。
8.海洋真菌Phomopsis tersa FS441在制备权利要求1中的tersaphilone B和/或tersaphilone E中的应用,所述的应用是按照权利要求2所述的制备方法制备得到tersaphilone B和/或tersaphilone E。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010647520.7A CN111808088B (zh) | 2020-07-07 | 2020-07-07 | 化合物tersaphilone B和E及其制备方法和在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010647520.7A CN111808088B (zh) | 2020-07-07 | 2020-07-07 | 化合物tersaphilone B和E及其制备方法和在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111808088A CN111808088A (zh) | 2020-10-23 |
CN111808088B true CN111808088B (zh) | 2022-10-11 |
Family
ID=72841884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010647520.7A Active CN111808088B (zh) | 2020-07-07 | 2020-07-07 | 化合物tersaphilone B和E及其制备方法和在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111808088B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116284035B (zh) * | 2023-03-14 | 2024-04-30 | 中国科学院南海海洋研究所 | 海洋真菌来源开环吲哚二萜类化合物peniditerpenoid A及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111004251A (zh) * | 2019-10-31 | 2020-04-14 | 广东省微生物研究所(广东省微生物分析检测中心) | 海洋来源杂萜化合物i和ii、制备方法及其在制备抗肿瘤药物中的应用 |
-
2020
- 2020-07-07 CN CN202010647520.7A patent/CN111808088B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111004251A (zh) * | 2019-10-31 | 2020-04-14 | 广东省微生物研究所(广东省微生物分析检测中心) | 海洋来源杂萜化合物i和ii、制备方法及其在制备抗肿瘤药物中的应用 |
Non-Patent Citations (3)
Title |
---|
Chaephilones A and B, Two New Azaphilone Derivatives Isolated from Chaetomium globosum;Chunmei Chen et al.;《Chem Biodivers.》;20160430;第13卷(第4期);第422-426页 * |
Isochromophilones A–F, Cytotoxic Chloroazaphilones from the Marine Mangrove Endophytic Fungus Diaporthe sp. SCSIO 41011;Xiaowei Luo et al.;《J.Nat. Prod.》;20180308;第81卷;第934-941页 * |
Tersone A-G,New Pyridone Alkaloids from the Deep-Sea Fungus Phomopsis tersa;Shan-Chong Chen et al.;《Mar. Drugs》;20190703;第17卷;第394页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111808088A (zh) | 2020-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110642827B (zh) | 化合物photeroids A和B及其制备方法和在制备抗肿瘤药物中的应用 | |
CN109336873B (zh) | 化合物lithocarolsA-F及其制备方法和在制备抗肿瘤药物中的应用 | |
CN112592350B (zh) | 聚酮类化合物lithocarpin E-G及其制备方法和应用 | |
CN109232513B (zh) | 化合物lithocarpinols及其制备方法和在制备抗肿瘤药物中的应用 | |
Gaur et al. | In vitro antimalarial studies of novel artemisinin biotransformed products and its derivatives | |
CN111004251B (zh) | 海洋来源杂萜化合物i和ii、制备方法及其在制备抗肿瘤药物中的应用 | |
CN111808088B (zh) | 化合物tersaphilone B和E及其制备方法和在制备抗肿瘤药物中的应用 | |
CN106967024A (zh) | 一种α‑吡喃酮衍生物及其制备方法和应用 | |
CN109776561B (zh) | 化合物cytorhizins B和C及其制备方法和在制备抗肿瘤药物中的应用 | |
CN110862371B (zh) | 多环聚酮类化合物及其制备方法和在制备抗菌药物中的应用 | |
CN114213428B (zh) | 一种吲哚生物碱化合物及其制备方法和应用 | |
CN107501072B (zh) | 化合物colletotriconeA及其制备方法和在制备抗肿瘤药物中的应用 | |
CN113603594B (zh) | 倍半萜类化合物及其制备方法和在制备抗肿瘤药物中的应用 | |
CN102746995B (zh) | 制备isochromophilone VIII的方法及其在制备抗肿瘤药物中的应用 | |
CN111471050B (zh) | 一类星孢菌素类衍生物及其制备方法和应用 | |
CN112500374B (zh) | 化合物tenellone K及其制备方法和在制备抗肿瘤药物中的应用 | |
CN113480557B (zh) | 聚酮类化合物及其制备方法和在制备抗肿瘤药物中的应用 | |
CN112300188B (zh) | 化合物myrothecine H和I及其制备方法和应用 | |
CN114605430B (zh) | 一种大环双内酯类化合物及其制备方法和应用 | |
CN111205308B (zh) | 一种硫代二酮哌嗪类化合物及其制备方法和应用 | |
CN114891017B (zh) | 一种马来酸酐脂环类化合物及其制备方法和应用 | |
CN113651677B (zh) | 化合物eutyscoparins G及其制备方法和在制备抗菌药物中的应用 | |
CN115650854B (zh) | 整合素衍生物及其制备方法和在α-葡萄糖苷酶抑制药物等方面的应用 | |
CN111777533B (zh) | 一类异戊烯基砜酰胺类化合物及其制备方法和用途 | |
CN108186627B (zh) | 化合物helicascolide A在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee after: Institute of Microbiology, Guangdong Academy of Sciences Address before: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee before: GUANGDONG INSTITUTE OF MICROBIOLOGY (GUANGDONG DETECTION CENTER OF MICROBIOLOGY) |